Edition:
United States

Sunesis Pharmaceuticals Inc (SNSS.OQ)

SNSS.OQ on NASDAQ Stock Exchange Capital Market

2.51USD
23 May 2018
Change (% chg)

$-0.27 (-9.71%)
Prev Close
$2.78
Open
$2.77
Day's High
$2.83
Day's Low
$2.48
Volume
27,429
Avg. Vol
50,208
52-wk High
$7.68
52-wk Low
$1.84

Chart for

About

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $56.67
Shares Outstanding(Mil.): 23.51
Dividend: --
Yield (%): --

Financials

  SNSS.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -1.94 -- --
ROI: -174.35 1.57 14.38
ROE: -- 2.43 16.07

BRIEF-Sunesis Pharmaceuticals Qtrly Loss Per Share $0.21

* SUNESIS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

May 08 2018

BRIEF-Sunesis Pharmaceuticals Announces Cancellation Of Presentation And Webcast At Cowen & Company 38Th Annual Health Care Conference

* SUNESIS PHARMACEUTICALS ANNOUNCES CANCELLATION OF PRESENTATION AND WEBCAST AT COWEN & COMPANY 38TH ANNUAL HEALTH CARE CONFERENCE

Mar 13 2018

BRIEF-Sunesis Pharma Qtrly Loss Per Share $0.21

* SUNESIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

Mar 08 2018

BRIEF-Boxer Capital Llc Reports 6.2 Percent Passive Stake In Sunesis Pharmaceuticals Inc

* BOXER CAPITAL, LLC REPORTS 6.2 PERCENT PASSIVE STAKE IN SUNESIS PHARMACEUTICALS INC AS OF FEBRUARY 21, 2018 Source text: (http://bit.ly/2H6YWUT) Further company coverage:

Mar 05 2018

BRIEF-Sunesis Pharmaceuticals Inc - Daniel Swisher Resigns As CEO Effective End Of 2017

* SUNESIS PHARMACEUTICALS INC - DANIEL SWISHER RESIGNS AS CEO EFFECTIVE END OF 2017

Dec 04 2017

BRIEF-Sunesis Pharmaceuticals Appoints William Quinn As CFO

* SUNESIS PHARMACEUTICALS APPOINTS WILLIAM QUINN AS CHIEF FINANCIAL OFFICER AND SENIOR VICE PRESIDENT, FINANCE AND CORPORATE DEVELOPMENT

Nov 30 2017

Competitors

  Price Chg
Eisai Co., Ltd (4523.T) ¥8,013 --
Johnson & Johnson (JNJ.N) $123.45 +0.54
Novartis AG (NOVN.S) CHF76.16 -0.52
Pfizer Inc. (PFE.N) $35.97 +0.25
Merck & Co., Inc. (MRK.N) $59.17 +0.72
Celgene Corporation (CELG.OQ) $77.66 +1.05

Earnings vs. Estimates